For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Biosplice Therapeutics, Inc.

USPTO Granted Patents = 18

EPO Patents = 5

Trademarks = 7

Forward Citations = 34

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Sunil Kumar Kc (14 out of 124 patents)

John Hood (9 out of 121 patents)

Gopi Kumar Mittapalli (6 out of 23 patents)

4. Chi Ching Mak (6 out of 33 patents)

5. Chandramouli Chiruta (5 out of 58 patents)

6. Jianguo Cao (5 out of 84 patents)

7. Luis A Dellamary (4 out of 74 patents)

8. Brian Joseph Hofilena (4 out of 14 patents)

9. Brian Walter Eastman (4 out of 33 patents)

10. David Mark Wallace (4 out of 118 patents)

11. Venkataiah Bollu (3 out of 26 patents)

12. Joseph Timothy Marakovits (3 out of 20 patents)

13. Charlene F Barroga (3 out of 16 patents)

14. Yusuf Yazici (2 out of 5 patents)

15. Christopher Swearingen (2 out of 5 patents)

18 patents: Sort by Forward Citations

1. 12281097 - Isoquinolin-3-yl carboxamides and preparation and use thereof (2025-04-21),

2. 12134625 - Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof (2024-11-05),

3. 12012401 - Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide (2024-06-18),

4. 11839679 - Gamma-diketones for treatment and prevention of aging skin and wrinkles (2023-12-12),

5. 11819499 - Single-dose, ready-to-use injectable formulations (2023-11-21),

6. 11780823 - Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors (2023-10-10),

7. 11713320 - 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof (2023-08-01),

8. 11697649 - Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof (2023-07-11),

9. 11684615 - Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors (2023-06-27),

10. 11673885 - γ-diketones as Wnt/β-catenin signaling pathway activators (2023-06-13),

11. 11673881 - Isoquinolin-3-yl carboxamides and preparation and use thereof (2023-06-13),

12. 11667632 - 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof (2023-06-06),

13. 11560378 - Treatment of osteoarthritis (2023-01-24),

14. 11548872 - Isoquinolin-3-yl carboxamides and preparation and use thereof (2023-01-10),

15. 11446288 - Single-dose, ready-to-use injectable formulations (2022-09-20),

Biosplice Therapeutics, Inc. is a biotechnology company focused on developing innovative RNA splice-modulating therapies. Our cutting-edge research aims to address unmet medical needs in various disease areas, including oncology and rare genetic disorders. With a team of experienced scientists and industry experts, we are committed to advancing new treatment options for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

18 Patents

#307 in San Diego, CA

#4,145 in California

#17,382 in US

#33,147 in the World

San Diego, CA, United States of America

Biosplice Therapeutics, Inc.

Forward Citations = 34

21 inventors:

Sunil Kumar Kc (14 out of 124 patents)

John Hood (9 out of 121 patents)

Gopi Kumar Mittapalli (6 out of 23 patents)

4. Chi Ching Mak (6 out of 33 patents)

5. Chandramouli Chiruta (5 out of 58 patents)

Please report any incorrect information to support@idiyas.com

Loading…